The ReSPonD study - Rivastigmine to Stabilise gait in Parkinson?s Disease

Phase 2

Completed

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN19880883
• Lead Sponsor: niversity of Bristol (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08-26
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

1. Patients with moderate (Hoehn and Yahr stage 2-3) PD.
2. History of having fallen at least once in the last year
3. Participants must be able to walk, without aids, for the length of the walking protocol (approximately 18m)
4. Stable on anti-Parkinsonian medication for 2 weeks prior to enrolment
5. Able to give informed consent and willing to participate

Exclusion Criteria

1. Patients with any other cause [vascular, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), normal pressure hydrocephalus) of Parkinsonism
2. Known diagnosis of dementia
3. Patients with other neurological, visual or orthopaedic problems that significantly interfere with balance or gait
4. Previous or current treatment with a cholinesterase inhibitor or absolute contraindication to cholinesterase inhibitor therapy
5. Inability to attend or comply with treatment or follow-up scheduling
6. Non-English speaking patients, as cognitive tests will be performed in English

Study & Design

• Study Type: Interventional
• Study Design: Not specified